Cardax

Cardax Current Liabilities

The Current Liabilities of Cardax (CDXI) as of Oct 19, 2026 is 10.55 M USD. In the previous year, Current Liabilities was 8.13 M USD — a change of 29.73% (higher).

Current Liabilities

10.55 MUSD

YoY

29.73%

Last updated:

Current Liabilities of Cardax is 2020 10.55 M USD. Current Liabilities of Cardax was 2019 8.13 M USD. It decreases by 29.73% higher compared to the previous year.

The Cardax Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2015
4.60 M USD
Jan 1, 2016
4.64 M USD
Jan 1, 2017
4.56 M USD
Jan 1, 2018
5.90 M USD
Jan 1, 2019
8.13 M USD
Jan 1, 2020
10.55 M USD
The Cardax Current Liabilities history
YEARCurrent LiabilitiesYoY
10.55 MUSD+29.73%
8.13 MUSD+37.81%
5.90 MUSD+29.36%
4.56 MUSD-1.60%
4.64 MUSD+0.79%
4.60 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cardax Stock analysis

What does Cardax do? Cardax Inc, a development stage biopharmaceutical company based in Honolulu, Hawaii, focuses on developing pharmaceuticals for chronic diseases driven by inflammation. The company has 10 full-time employees and went public via an IPO on January 30, 2012. Cardax is currently developing two pre-clinical pharmaceutical candidates: CDX-101 and CDX-301. CDX-101 is a proprietary astaxanthin prodrug designed to deliver astaxanthin to the bloodstream following oral administration. Astaxanthin is a naturally occurring molecule known for its anti-inflammatory properties, supporting cardiovascular health, metabolic health, liver health, joint health, and longevity. CDX-301 is a pharmaceutical candidate for macular degeneration, utilizing zeaxanthin, which accumulates in the human eye through a retinal receptor to protect against blue light, oxidative damage, and inflammation associated with macular degeneration. The company's headquarters are located in Honolulu, and it operates within the Health Care sector, specifically in the Pharmaceuticals industry. Cardax Inc's website is https://cardaxpharma.com/. The company is seeking to monetize its pre-clinical candidates, CDX-101 and CDX-301, as it advances its development pipeline. No additional details about the company's financials, specific acquisition history, or other product names are provided in the available information. Cardax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cardax stock

Current Liabilities of Cardax is 10.55 M USD in 2020.

Current Liabilities of Cardax changed from 8.13 M USD to 10.55 M USD, representing a 29.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Cardax since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Cardax historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cardax

All Key Metrics — Cardax